Management of Type 2 Diabetes Mellitus with Basal-Prandial Insulin Therapy: A Case-Based Review

Insulin

Volumn 2, Issue 3, 2007, Pages 118-126

  Davis, Stephen N ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

complications; hyperglycemia; insulin; type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HYDROCHLOROTHIAZIDE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LEVOTHYROXINE; LISINOPRIL; METFORMIN; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; DIABETES CONTROL; DIET THERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FOLLOW UP; FREE THYROXINE INDEX; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTHYROIDISM; INFORMATION RETRIEVAL; INSULIN TREATMENT; INTENSIVE CARE; KINESIOTHERAPY; LONG TERM CARE; MALE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT EDUCATION; POSTPRANDIAL STATE; RISK REDUCTION; SELF MONITORING; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT RESPONSE;

EID: 34548018295     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(07)80040-6     Document Type: Article

References (56)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: United States, 2005. General information (2005). http://www.cdc.gov/od/oc/media/pressrel/fsO51026.htm Available at: http://www.cdc.gov/od/oc/media/pressrel/fsO51026.htm. Accessed March 15, 2005
2. Boyle J., Honeycutt A., Narayan K., et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 24 (2001) 1936-1940
3. McBean A., Li S., Gilbertson D., and Collins A. Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: Whites, blacks, Hispanics, and Asians. Diabetes Care 27 (2004) 2317-2324
4. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 23 (2000) 381-389
5. Nathan D. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347 (2002) 1342-1349
6. Haffner S., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
7. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
8. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
9. American Diabetes Association. Standards of medical care in diabetes-2006. published correction appears in. Diabetes Care 29 (2006) 1192
10. American Diabetes Association. Standards of medical care in diabetes-2006. published correction appears in. Diabetes Care 29 Suppl 1 (2006) S4-S42
11. American Association of Clinical Endocrinologists. Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement, February 2, 2005. Available at: (2005). http://www.aace.com/pub/pdf/guidelines/OutpatientImplementationPositionStatement.pdf Accessed March 14, 2005
12. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. published correction appears in. Diabetes 45 (1996) 1655
13. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. published correction appears in. Diabetes 44 (1995) 1249-1258
14. Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract 12 Suppl 1 (2006) 89-92
15. Tokinaga K., Oeda T., Suzuki Y., and Matsushima Y. HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr J. 53 (2006) 401-405
16. Synthroid [package insert] (2005), Abbott Laboratories, North Chicago, II1
17. Hundal R., Krssak M., Dufour S., et al. Mechanism by which met-formin reduces glucose production in type 2 diabetes. Diabetes 49 (2000) 2063-2069
18. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA 287 (2002) 360-372
19. Herman G., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91 (2006) 4612-4619
20. Sitagliptin (Januvia) for type 2 diabetes. Med Lett Drugs Ther 49 (2007) 1-3
21. Nichols G., Alexander C., Girman C., et al. Treatment escalation and rise in HbAlc following successful initial metformin therapy. Diabetes Care 29 (2006) 504-509
22. Ilkova H., Glaser B., Tunckale A., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20 (1997) 1353-1356
23. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 32 Suppl 1 (2006) 9S-18S
24. Dailey III G., Noor M., Park J., et al. Glycemic control with glyburide/mefformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med 116 (2004) 223-229
25. Schwartz S., Sievers R., Strange P., et al. for the INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: Efficacy, safety, and cost analysis. Diabetes Care 26 (2003) 2238-2243
26. Rosenstock J., Sugimoto D., Strange P., et al. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29 (2006) 554-559
27. Hirsch I. Insulin analogues. N Engl J Med 352 (2005) 174-183
28. Cefalu W., Skyler J., Kourides I., et al. for the Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134 (2001) 203-207
29. Plank J., Bodenlenz M., Sinner F., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28 (2005) 1107-1112
30. Chapman T., and Perry C. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs 19 (2005) 67-69
31. Riddle M., Rosenstock J., and Gerich J. for the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
32. Kennedy L., Herman W., Strange P., and Harris A. for the GOAL AIC Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1C on glycemic control in patients with type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 29 (2006) 1-8
33. Davies M., Storms F., Shutler S., et al. for the ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly conlrolled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
34. Fritsche A., Schweitzer M., and Haring H. for the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 138 (2003) 952-959
35. Rosenstock J., Schwartz S., Clark Jr. C., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
36. Douek I., Allen S., Ewings P., et al. Continuing metformin when starting insulin in patients with type 2 diabetes: A double-blind randomized placebo-controlled trial. Diabet Med 22 (2005) 634-640
37. Janka H., Plewe G., Riddle M., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
38. Raskin P., Allen E., Hollander P., et al. for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
39. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
40. Heine R., Van Gaal L., Johns D., et al. for the GWAA Study Group. Exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 143 (2005) 559-569
41. Kendall D., Riddle M., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
42. DeFronzo R., Ratner R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
43. Buse J., Henry R., Han J., et al. for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
44. Davis S., Johns P., Maggs D., et al. Substituting exenatide for insulin in patients with type 2 diabetes: An exploratory study. Diabetes 55 Suppl 1 (2006) A109
45. Blonde L., Klein E., Han J., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 8 (2006) 436-447
46. Riddle M., Henry R., Poon T., et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev. 22 (2006) 483-491
47. Ryan G., Jobe L., and Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 27 (2005) 1500-1512
48. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(lc). Diabetes Care 26 (2003) 881-885
49. Gerich J. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 163 (2003) 1306-1316
50. Pettitt D., Knowler W., Lisse J., and Bennett P. Development of retinopathy and proteinuria in relation to plasma-glucose concentrations in Pima Indians. Lancet 2 (1980) 1050-1052
51. DeWitt D., and Hirsch l. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 289 (2003) 2254-2264
52. Garg S., Rosenstock J., and Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glufisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 11 (2005) 11-17
53. Raslova K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. [published correction appears in]. Diabetes Res Clin Pract. 72 (2006) 112
54. Raslova K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. [published correction appears in]. Diabetes Res Clin Pract. 66 (2004) 193-201
55. Ashwell S., Amiel S., Bilous R., et al. Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med. 23 (2006) 285-292
56. Bergenstal R., Johnson M., Powers M., et al. Using a simple algorithm (ALG) to adjust mealtime glulisine (GLU) based on pre-prandial glucose palterns is a safe and effective alternative to carbohydrate counting (carb count). Diabetes 55 Suppl 1 (2006) A105